Insights

‘The largest unmet medical need in human health’: Why this ASX biotech share is surging 28% today

Recce shares are flying high in Tuesday trade.
The post ‘The largest unmet medical need in human health’: Why this ASX biotech share is surging 28% today appeared first on The Motley Fool Australia. –

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is rebounding after hitting a near multi-year low of 56 cents yesterday.

This comes after the pharmaceutical company provided an update on its development of a new class of synthetic anti-infectives.

At the time of writing, the ASX biotech share is soaring 28.32% to 73 cents.

What’s pushing the Recce share price higher?

The company has reported positive results for its broad-spectrum antibiotic Recce 327 drug today.

The phase I study assessed the safety and tolerability of Recce 327 in patients with sepsis.

As such, investigators reviewed the data and found that all 10 male subjects indicated a good safety and tolerability record.

The healthy patients received the cohort six dosing at 4,000mg – an 80-fold increase from cohort one at 50mg.

Following the successful results, the Independent Safety Committee will carefully review the cohort six data. Once completed, the Committee will make a recommendation for the dosage limit and the commencement of testing with the next group of patients.

What did Recce management say?

Recce CEO James Graham commented:

We are pleased with these data which builds on previous results and strongly supports the potential of RECCE 327 as a new treatment option for patients with sepsis.

We look forward to continuing to work with the Independent Safety Committee and further evaluating RECCE 327’s safety and tolerability profile in additional cohorts.

Recce is conducting the study at Adelaide’s CMAX clinical trial facility. It is seeking to evaluate seven to 10 healthy subjects per dose across eight cohorts.

Recce is aiming to wrap up the phase I trial by the second quarter of 2022.

In addition, the PEW Charitable Trusts global antibiotic pipeline review noted that “R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health”.

Recce share price snapshot

The ASX biotech share has tumbled 33% in 2022 despite today’s outstanding gains.

For context, the S&P/ASX 200 Healthcare (ASX: XHJ) sector is down 15% over the same time frame.

Based on today’s price, Recce presides a market capitalisation of roughly $113.71 million.

The post ‘The largest unmet medical need in human health’: Why this ASX biotech share is surging 28% today appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of January 12th 2022

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

2 good reasons to become an ESG investor — and 1 reason you shouldn’t
Fortescue share price rebounds 3% today
What’s boosting the Qantas share price on Tuesday?
How to start investing in stocks: This ASX 200 share is where I’d begin
Here’s why the Beach Energy share price is leaping 4% today

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info